A safety and efficacy analysis of direct-antiviral therapy in patients with chronic hepatitis C after renal transplantation.

ABSTRACT:

Background

To explore the safety and efficacy of direct antiviral therapy in patients with hepatitis C virus (HCV) infection after renal transplantation.

Methods

We retrospectively reviewed the medical information of 15 cases of HCV⁺ patients treated with direct antiviral therapy after renal transplantation in our center. The effectiveness of direct antiviral therapy was evaluated by analyzing the HCV-RNA levels of patients at 1, 4, 12, 24, and 48 weeks before and after antiviral therapy. In addition, parameters including the rejection rate, the blood concentration of anti-rejection drugs, liver function level [alanine aminotransferase (ALT), aspartate transaminase (AST)], estimated glomerular filtration rate (eGFR) and serum creatinine (CREA) levels were used to

SUBMITTER: Li G 

PROVIDER: S-EPMC7215012 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature